• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Press release

Enzymatica AB: ColdZyme launches a refreshing new flavour - Eucalyptus

Enzymatica

Enzymatica expands the ColdZyme® range with a new flavour - Eucalyptus. The new flavour offers the same barrier technology and clinically proven benefit against common cold viruses, now with a fresh and cooling taste experience. 

Like other products in the series, ColdZyme Eucalyptus creates a protective barrier in the throat that helps reduce the viral load, shorten the duration of a cold, and relieve symptoms. The ColdZyme range previously included menthol and strawberry flavours - with Eucalyptus now introduced as a fresh, cooling alternative.  

"With ColdZyme Eucalyptus, we want to give consumers another choice - without compromising on quality or performance. Many associate eucalyptus with freshness and free breathing, making it a natural addition to our portfolio," says Claus Egstrand, CEO of Enzymatica AB. 

The launch of ColdZyme Eucalyptus will take place in October in Sweden. The product will be available in pharmacies and online.

ColdZyme has been shown in peer-reviewed studies[1] to reduce viral load by up to 94 percent and shorten the duration of a cold by an average of 40 percent.

About ColdZyme®

ColdZyme® is a CE-marked mouth spray designed to create a protective barrier in the throat. It is supported by clinical studies showing reduced duration and severity of common colds when used as directed. Read more about the latest independent study here: https://coldzyme.enzymatica.com

ColdZyme® is a registered trademark of Enzymatica AB. Always read the label and instructions for use.

References
[1] Davison G et al. 2025  ColdZyme® reduces viral load and upper respiratory tract infection duration and protects airway epithelia from infection with human rhinoviruses. The Journal of Physiology. 2025;603(6):1483-1501. doi:10.1113/JP288136. PubMed: 40019230. https://physoc.onlinelibrary.wiley.com/doi/10.1113/JP288136